Jing Li, Xingzuo Liu, Zhiming Zhang, Hequn Wang, Jingbo Ma, Yanwen Jiang, Le Sheng, Shumei Li, Ji Zhang, Xinrong Lin, Kungchi Hsu, Yidong Tu, Andrew Steel, Yan Wu, Frederic Flament
{"title":"Efficacy and Tolerability of a Facial Serum Before and After Ablative Fractional Carbon Dioxide Laser: A Randomized Controlled Trial on Chinese Women.","authors":"Jing Li, Xingzuo Liu, Zhiming Zhang, Hequn Wang, Jingbo Ma, Yanwen Jiang, Le Sheng, Shumei Li, Ji Zhang, Xinrong Lin, Kungchi Hsu, Yidong Tu, Andrew Steel, Yan Wu, Frederic Flament","doi":"10.1007/s13555-025-01531-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Ablative fractional CO<sub>2</sub> laser treatment (AFCO<sub>2</sub>) can cause immediate erythema, pain, and complications such as prolonged erythema and post-inflammatory hyperpigmentation. This study investigated whether the use of a serum before and after AFCO<sub>2</sub> could accelerate skin recovery and relieve complications.</p><p><strong>Methods: </strong>This randomized controlled trial included 72 healthy Chinese women with acne scars who intended to undergo AFCO<sub>2</sub>; 64 (32 in each group) completed the study and were included in the analysis. The participants in the serum group applied the study serum for 2 weeks in the preoperative (D0 and D14) and post-treatment stages (D32 and D39), with additional product usage of standard products, including standard cleanser, moisturizer, and sunscreen, for all participants (both groups). Transepidermal water loss (TEWL), skin hydration, and skin qualities were evaluated throughout the entire study. Clinical assessment was conducted at D0 (baseline and time immediately after product application); D14; D15 (directly after procedure treatment); D16, D18, D22, and D25 (1 day, 3 days, 7 and 10 days after CO<sub>2</sub> laser treatment); and during the post-treatment period at D32 and D39 (1 and 2 weeks after self-recovery).</p><p><strong>Results: </strong>TEWL improvement was significantly better in the serum group than in the control group throughout the study (p < 0.001), including pre-treatment (p = 0.043), self-recovery (D15-D31) (p < 0.001), and post-treatment (p = 0.027) stages. In the post-treatment stage, the improvement in skin hydration with the serum was significantly better than in the control group (p < 0.001). The serum group showed significantly better improvements in smoothness (p = 0.001), brightness (p = 0.016), and overall healthy appearance (p = 0.001) compared with controls.</p><p><strong>Conclusion: </strong>Peri-AFCO<sub>2</sub> application of the serum can facilitate faster postoperative recovery and can help reduce postoperative erythema and discomfort with satisfying tolerance. The use of the serum can enhance effectiveness and satisfaction with AFCO<sub>2</sub> treatment.</p><p><strong>Trial registration: </strong>This trial was retrospectively registered on 30 June 2025: ISRCTN identifier ISRCTN60519611.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01531-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Ablative fractional CO2 laser treatment (AFCO2) can cause immediate erythema, pain, and complications such as prolonged erythema and post-inflammatory hyperpigmentation. This study investigated whether the use of a serum before and after AFCO2 could accelerate skin recovery and relieve complications.
Methods: This randomized controlled trial included 72 healthy Chinese women with acne scars who intended to undergo AFCO2; 64 (32 in each group) completed the study and were included in the analysis. The participants in the serum group applied the study serum for 2 weeks in the preoperative (D0 and D14) and post-treatment stages (D32 and D39), with additional product usage of standard products, including standard cleanser, moisturizer, and sunscreen, for all participants (both groups). Transepidermal water loss (TEWL), skin hydration, and skin qualities were evaluated throughout the entire study. Clinical assessment was conducted at D0 (baseline and time immediately after product application); D14; D15 (directly after procedure treatment); D16, D18, D22, and D25 (1 day, 3 days, 7 and 10 days after CO2 laser treatment); and during the post-treatment period at D32 and D39 (1 and 2 weeks after self-recovery).
Results: TEWL improvement was significantly better in the serum group than in the control group throughout the study (p < 0.001), including pre-treatment (p = 0.043), self-recovery (D15-D31) (p < 0.001), and post-treatment (p = 0.027) stages. In the post-treatment stage, the improvement in skin hydration with the serum was significantly better than in the control group (p < 0.001). The serum group showed significantly better improvements in smoothness (p = 0.001), brightness (p = 0.016), and overall healthy appearance (p = 0.001) compared with controls.
Conclusion: Peri-AFCO2 application of the serum can facilitate faster postoperative recovery and can help reduce postoperative erythema and discomfort with satisfying tolerance. The use of the serum can enhance effectiveness and satisfaction with AFCO2 treatment.
Trial registration: This trial was retrospectively registered on 30 June 2025: ISRCTN identifier ISRCTN60519611.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
